Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$64.58
pos +0.27
+0.42%
Today's Range: 64.21 - 64.83 | GILD Avg Daily Volume: 7,932,600
Last Update: 05/25/17 - 3:59 PM EDT
Volume: 5,639,543
YTD Performance: -10.19%
Open: $64.50
Previous Close: $64.31
52 Week Range: $77.92 - $120.37
Oustanding Shares: 1,306,728,398
Market Cap: 84,532,260,067
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 9 10 10 11
Moderate Buy 1 1 1 1
Hold 9 9 9 8
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.00 1.95 1.95 1.85
Latest Dividend: 0.52
Latest Dividend Yield: 3.22%
Dividend Ex-Date: 06/14/17
Price Earnings Ratio: 6.84
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
6.84 6.80 29.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-8.05% -25.41% -20.55%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.90 1.70 0.39
Net Income -25.50 3.40 0.63
EPS -16.50 4.00 0.70
Earnings for GILD:
EBITDA 18.79B
Revenue 30.39B
Average Earnings Estimates
Qtr (06/17) Qtr (09/17) FY (12/17) FY (12/18)
Average Estimate $2.04 $1.94 $7.88 $7.41
Number of Analysts 6 5 8 3
High Estimate $2.17 $2.02 $8.31 $8.46
Low Estimate $1.87 $1.84 $6.86 $6.26
Prior Year $3.03 $2.70 $11.37 $7.88
Growth Rate (Year over Year) -32.67% -28.22% -30.66% -6.05%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
RMPIA
By

Doug Kass

 | May 23, 2017 | 3:44 PM EDT
"There are two kinds of spurs, my friend. Those that come in by the door; those that come in by the window.." -- Tuco, "
RMPIA
By

Doug Kass

 | May 16, 2017 | 2:34 PM EDT
"A value trap is a stock that appears to be cheap because the stock has been trading at low multiples of earnings, cash flow or …
RMPIA
By

Doug Kass

 | May 8, 2017 | 4:38 PM EDT
"She's a witch of trouble in electric blue, In her own mad mind she's in love with you. With you. Now what you gonna do? Strange brew, kill w …
RMPIA
By

Doug Kass

 | May 8, 2017 | 12:33 PM EDT
Allergan (AGN) , a day ahead of its earnings release, is down by over $4 on no apparent news, save a rotation out of biotech. (iShares Nasdaq Biotechnology (IBB) is -3% or -$7 and we see individual equity declines in Celgene (CELG) , Gilead (GILD) , Acadia Pharmaceuticals (ACAD) , Aerie Pharmaceuticals (AERI) , and Intrexon (XON) ).
RMPIA
By

Doug Kass

 | May 3, 2017 | 4:12 PM EDT
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly"
RMPIA
By

Bret Jensen

 | May 3, 2017 | 11:40 AM EDT
How did Celgene, AbbVie and Gilead fare last quarter?
RMPIA
By

Bob Byrne

 | May 3, 2017 | 7:00 AM EDT
Nearly anything associated with oil and gas drilling gets crushed.
RMPIA
By

Bret Jensen

 | Apr 26, 2017 | 11:30 AM EDT
Biotech investors should keep a close eye on the progress in this huge potential market.
RMPIA
By

Doug Kass

 | Apr 25, 2017 | 3:17 PM EDT
* Biotech (Allergan (AGN) , Celgene (CELG) and Gilead Sciences (GILD) ) * Speculative biotech ( ZIOPHARM Oncology (ZIOP) ,   SAGE Therapeutics (SAGE) , Intrexon (XON) , Valeant Pharmaceuticals (VRX) ,   ACADIA Pharmaceuticals (ACAD) , FibroGen  (FGEN) ). * DuPont (DD) , Netflix (NFLX) , Baidu (BIDU) , Radian (RDN) and Biogen   (BIIB) . * New tech - (T)FANG (TSLA) , (FB) , (AAPL) , (NFLX) , (GOOGL) . * Chipotle Mexican Grill (
RMPIA
By

Doug Kass

 | Apr 17, 2017 | 3:19 PM EDT
  Doug Kass frdgrouper1 • 2 hours ago Yes the character/complexion of the market may be in the process of changing. But in a world in which algos/machines control the daily action I will remain opportunistic and reactionary rather than dogmatic and anticipatory, The environment I see favors opportunistic traders. For those with a one year time frame - I would be medium sized short. But I am of the belief that I can trade actively, for a portion of my portfolio and capitalize on near term moves .... A number of reasons, many of which were cited in my bond piece. Above all I am trading opportunistically - trying to stay away from dogma and readjusting to events and prices. Some of Trump's moves, evidence that flight to safety may be abandoned over the short term, etc. I remain quite bearish over the intermediate term (3-1 downside/upside) but I have been dedicated to being more reactionary and less anticipatory - taking on positions (away from long/short investments) in trading rentals (leveraged ETFs, even put options as I did with SPY puts a few weeks ago) measured in days/weeks rather than weeks/months. It seems to be working ok.   I will have more on opportunistically trading tomorrow morning.   * The US Dollar weakened in today's trading session. * The price of crude oil fell by fifty cents to $52.70. * Gold rallied by +$2.70. (at $122.5 I would be a seller of (GLD) ). * Ag commodities got schmeissed (watch out fertilizers): wheat -8, corn -4.50, soybeans -1.50 and oats -4. * Lumber unchanged. * Interesting day in bonds - with a near five basis point move higher in yield from the day's lows. * On the day, yields +2-3 basis points. * The 2s/10s spread increased by two basis points to 105 basis points. * Junk rallied - I am laser focused on the spread to Treasuries. That spread is narrow relative to three months ago, suggesting some acceleration in domestic growth lies ahead. * Municipals were unchanged as were closed end muni bond fund prices. * Banks rallied, by only modestly so. * Brokerages were stronger - and as I suggested in my tactical piece on financials - could have room to run/ I plan to short, but will give the group a wider perch. * Insurance rallied. Hartford Financial Services (HIG) has a nice "look" to it. * Retail remains a mine field of disappointment. * Autos better on a Barrons Ford (F) push. Still very much a value trap to me. * Biotech lagged with Allergan (AGN) and Gillead (GILD) weak. Speculative biotech little price action. * Big pharma hurt by Incyte/Lilly (INCY) / (LLY) news. * Ag equipment up - both Deere (DE) and Caterpillar (CAT) up two bits. * Consumer staples well bid. Campbell Soup (CPB) better after Thursday's weakness. * Media is mixed with Disney (DIS) on the upside. * Fertilizers had a small bid despite a weakening agricultural commodities complex. * Rails higher, but fractionally so. * The optical space was flat today - OCLR has no bounce and I still am indifferent towards name which has been accumulated by some with an eye at a takeover (seems unlikely). * (T)FANG still an upside market feature - though Tesla (TSLA) down a deuce. Amazon (AMZN) is still a monster. * In individual names, Apple (AAPL) up two bits after recent weakness. Bounces in Twitter (TWTR) and RDN. Here are some value added contributions on our site today: 1. Jim "El Capitan" Cramer likes the data " over there."  2. "Meet" Bret Jensen sees fading momentum in the markets.  Based on my moves today I can obviously see a better market, over the near term, so stay tuned. 3. RevShark looks like he could go either way (though he doesn't trust the upside that much) - he is a reactionary type of guy! (Who I hope to learn from one day!!) Here  and here 4. Divine Ms M is more in the rally camp (where I reside).  5. Bobby Lang dislikes Goldman Sachs (GS)  .I closed out my GS short profitably 1-2 weeks ago and I can see a rally in the name, subject to tomorrow's EPS report. The stock remains on my Best Ideas List and I plan to short on a +5% move or so.    
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.